Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
C21orf116
REST API REST API
Homo sapiens
C21orf116 is differentially expressed in 63 experiments: 35 organism parts: mammary gland, esophagus, ... (33 more);, 21 disease states: normal, Duchenne muscular dystrophy, ... (19 more);, 19 cell types 48 cell lines 4 compound treatments and 33 other conditions.
Synonyms PRED82
UniProt Accession Q9H386
Search EB-eye ENSG00000256895
Show more properties
Experimental Factors
Organism part

studied in E-MTAB-37, E-GEOD-18105, E-MTAB-69, E-AFMX-6, E-TABM-130, ... (9 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-MTAB-37, E-GEOD-5823, E-GEOD-20089, E-GEOD-19639, E-GEOD-19480, ... (9 experiments)

Factor Value U/D Experiments
EB2
1
E-MTAB-37
Caki2
1
E-MTAB-37
MKN74
1
E-GEOD-15460
SUDHL16
1
E-MTAB-37
Ist1
1
E-GEOD-15460
SW962
1
E-MTAB-37
42 more value(s).


Cell type

studied in E-GEOD-13987, E-GEOD-18811, E-MEXP-2360, E-GEOD-22373, E-GEOD-20033, ... (11 experiments)

Factor Value U/D Experiments
macrophage
1
E-GEOD-22373
monocyte
1
E-GEOD-22373
squamous cell carcinoma
1
E-GEOD-17347
fibroblast
1
E-GEOD-26672
plasma cell
1
E-MEXP-2360
B cell
1
1
E-GEOD-13987
13 more value(s).


Disease state

studied in E-GEOD-4290, E-GEOD-3307, E-GEOD-6338, E-GEOD-19743, E-MTAB-37, ... (11 experiments)

Factor Value U/D Experiments
normal
1
2
E-GEOD-6338, E-GEOD-7307, E-GEOD-13501
Hodgkin lymphoma
1
E-MTAB-37
normospermic
1
E-GEOD-6872
cervical carcinoma
1
E-MTAB-37
Duchenne muscular dystrophy
1
E-GEOD-3307
adenoma
1
E-GEOD-15960
15 more value(s).


Compound treatment

studied in E-GEOD-3284, E-GEOD-7307, E-GEOD-20081

Factor Value U/D Experiments
Cxcl12
1
E-GEOD-7307
not specified
1
E-GEOD-20081
bacterial endotoxin
1
1
E-GEOD-3284
control
10
1
E-GEOD-3284


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Cancer site
studied in E-GEOD-4271

Clinical history
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-21589, E-GEOD-16363

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-21589, E-GEOD-16363, E-GEOD-18995 ... (5 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-21138

Estrogen receptor status
studied in E-GEOD-6532

family id
studied in E-GEOD-19519

Genotype
studied in E-GEOD-17476, E-TABM-868, E-GEOD-17347

Growth condition
studied in E-GEOD-20540

Histology
studied in E-GEOD-21653

Individual
studied in E-TABM-325, E-GEOD-3284, E-MEXP-1243, E-GEOD-19519, E-MEXP-1648, ... (9 experiments)

Infection
studied in E-GEOD-12108, E-MEXP-561

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Metastasis
studied in E-GEOD-18105

Organism
studied in E-TABM-84

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-19246

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-20114

stimulus
studied in E-GEOD-22103

Test result
studied in E-TABM-276

Tumor grading
studied in E-GEOD-4271

Processing time: 0.499 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM